We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Molbio Exhibits Its Novel POC Molecular Platform and Truenat Range of Tests at MEDICA 2021

By LabMedica International staff writers
Posted on 16 Nov 2021

Molbio Diagnostics (Goa, India) exhibited its novel POC Truelab molecular platform and Truenat range of tests at MEDICA 2021, the leading international trade fair for the medical sector. More...

Molbio presented its fully automatic Truelab real time quantitative micro PCR system with a sample to results time of less than one hour. Among the Truelab systems presented at the event was the fully automatic Truelab Uno Dx real time quantitative micro PCR analyzer with a three wavelength system that performs 10-12 tests in eight hours. Molbio also highlighted the fully automatic Truelab Duo real time quantitative micro PCR analyzer with a two channel-three wavelength system that performs 20-24 tests in eight hours, alongside the fully automatic Truelab Quattro real time quantitative micro PCR analyzer with four channel-three wavelength system that performs 40-48 tests in eight hours. Molbio's Truelab also fits in a suitcase that can be transported easily anywhere and used by anyone. The platform can test over 30 diseases with a sample-to-result time of less than an hour, and the results can be transmitted instantly to any place via the IoT enabled platform.

Additionally, Molbio presented its Truenat range of disease-specific real time micro PCR tests at MEDICA 2021. The micro PCR chips are pre-loaded, ready-to-use and disposable. They are disease-specific and can be run on the Truelab Uno Dx/Duo/Quattro to get quantitative real-time PCR results. Among its wide range of Truenat real time micro PCR tests highlighted at the event was Truenat COVID-19, a chip-based RT PCR test for the semi quantitative detection of SARS CoV-2 RNA in human oropharyngeal and nasopharyngeal swab specimen. Molbio also showcased its WHO-endorsed Truenat MTB test for the quantitative detection and diagnosis of Mycobacterium tuberculosis (MTB) in human pulmonary and EPTB specimens that aids in the diagnosis of infection with MTB.

Related Links:
Molbio Diagnostics 


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.